Junshi Biosciences Reports the Result of VV116 in P-III to Treat COVID-19
Shots:
- The 2nd P-III study evaluating safety & efficacy of VV116 (mindeudesivir) vs PBO to treat COVID-19 patient (n=1296). The final analysis depicted a substantial reduction in time to sustained clinical symptoms with a median resolution time of 10.9 vs 12.9 days & HR of 1.22
- Additionally, day 5 of treatment showed a substantial increase in the SARS-CoV-2 Ct value as well as reduced viral load along with efficacy incl. substantial reduction in the amount of time needed for individuals to get long-lasting clinical symptom relief was observed despite the existence of high-risk factors for the development of severe COVID-19 immunization status
- VV116, an oral nucleoside analog that has the ability to prevent SARS-CoV-2 from replicating. The results will be published in the Lancet
Ref: Globenewswire | Image: Junshi Biosciences
Related News:- Junshi Biosciences Reports P-III Clinical Trial Results of VV116 for Severe COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
